57,710 Shares in Axon Enterprise, Inc $AXON Acquired by Danske Bank A S

Danske Bank A S acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 57,710 shares of the biotechnology company’s stock, valued at approximately $32,353,000.

Several other institutional investors have also added to or reduced their stakes in the business. Diversify Advisory Services LLC purchased a new position in shares of Axon Enterprise in the second quarter worth $370,000. Deepwater Asset Management LLC boosted its position in shares of Axon Enterprise by 98.1% during the second quarter. Deepwater Asset Management LLC now owns 17,933 shares of the biotechnology company’s stock valued at $10,053,000 after buying an additional 8,882 shares during the last quarter. Pension & Wealth Management Advisors Inc. boosted its position in shares of Axon Enterprise by 574.6% during the second quarter. Pension & Wealth Management Advisors Inc. now owns 796 shares of the biotechnology company’s stock valued at $446,000 after buying an additional 678 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in Axon Enterprise in the 2nd quarter worth about $444,000. Finally, Cornerstone Advisors LLC increased its holdings in Axon Enterprise by 64.1% in the 2nd quarter. Cornerstone Advisors LLC now owns 30,660 shares of the biotechnology company’s stock worth $17,188,000 after buying an additional 11,978 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 4.2%

Axon Enterprise stock opened at $645.72 on Thursday. The business has a 50-day simple moving average of $536.03 and a two-hundred day simple moving average of $474.89. The company has a market cap of $52.46 billion, a P/E ratio of 267.93, a P/E/G ratio of 10.06 and a beta of 1.39. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $794.29. The company has a quick ratio of 1.80, a current ratio of 2.15 and a debt-to-equity ratio of 0.47.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The firm had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. During the same quarter in the prior year, the firm earned $2.12 EPS. The business’s revenue for the quarter was up 35.3% compared to the same quarter last year. Analysts predict that Axon Enterprise, Inc will post 2.04 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the completion of the sale, the executive directly owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the transaction, the director owned 3,632 shares in the company, valued at $1,739,619.04. The trade was a 13.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 68,989 shares of company stock valued at $36,016,932 in the last three months. Corporate insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on AXON shares. Royal Bank Of Canada reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, July 21st. TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, July 22nd. Morgan Stanley boosted their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. The Goldman Sachs Group reissued a “buy” rating and set a $715.00 price objective on shares of Axon Enterprise in a report on Thursday, August 6th. Finally, Citizens Jmp restated a “market outperform” rating and set a $700.00 price objective on shares of Axon Enterprise in a research report on Thursday, June 25th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.